CytomX Therapeutics (NASDAQ:CTMX) Posts Earnings Results, Misses Estimates By $0.02 EPS

CytomX Therapeutics (NASDAQ:CTMX) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02), FiscalAI reports. CytomX Therapeutics had a negative return on equity of 35.54% and a negative net margin of 608.98%. The firm had revenue of $1.69 million during the quarter, compared to the consensus estimate of $10.38 million.

Here are the key takeaways from CytomX Therapeutics’ conference call:

• Varseta-M is advancing toward a potential registrational study: CytomX expects a January update with dose-optimization data and the first overall-survival readout, and is targeting study initiation in the first half of 2027. The company says overall survival is expected to be the primary endpoint, though the study population and design have not yet been finalized.
• The company is expanding Varseta-M’s development: It plans to begin a bevacizumab/chemotherapy combination study by year-end, with second-line patients expected in the Phase II portion, and anticipates initial bevacizumab-combination data in the first half of 2027. New cohorts are also evaluating the drug in gastric, gastroesophageal, pancreatic, and biliary cancers.
• Gastrointestinal toxicity remains a key development risk. CytomX reported a 10% rate of grade 3 diarrhea in the first 20 dose-optimization patients after two months of follow-up, versus more than 30% in time-matched earlier cohorts; it aims to keep the rate at or below 20%, but longer follow-up is pending.
• CytomX reported a cash runway into the second half of 2028 on $348 million in cash, equivalents, and investments at quarter-end, including a $37 million payment from Regeneron for two additional collaboration targets. Management said the funds support its stated Varseta-M development priorities.
• Quarterly revenue fell while operating expenses rose: Q3 revenue was $1.7 million, down from $6 million a year earlier, primarily following the end of the Astellas collaboration; operating expenses increased to $25.2 million from $21.7 million.

CytomX Therapeutics Price Performance

Shares of CTMX traded up $0.05 during midday trading on Friday, reaching $2.19. The stock had a trading volume of 2,727,216 shares, compared to its average volume of 4,190,396. The company’s 50-day moving average is $2.71 and its 200 day moving average is $3.81. CytomX Therapeutics has a 12-month low of $2.11 and a 12-month high of $8.21.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Guggenheim dropped their price target on CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a research report on Friday, September 11th. Zacks Research lowered shares of CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. JPMorgan Chase & Co. cut their price target on shares of CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a research note on Thursday, August 13th. Finally, Wall Street Zen raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CytomX Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Key Stories Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $12 from $11 and maintained an Outperform rating, signaling continued optimism about CytomX’s prospects. Wedbush Raises Price Target
• Positive Sentiment: Varseta-M reported 20%–32% objective response rates and a seven-month median progression-free survival in late-line colorectal cancer. The program has FDA Fast Track designation, with pivotal-trial initiation planned for the first half of 2027. The company also had $367 million in cash and potential partnership milestones, although those milestones are contingent on future development and commercial progress. CytomX Stock Trading Near Cash Value
• Negative Sentiment: Third-quarter revenue was $1.69 million, well below analyst expectations of $10.38 million. CytomX reported a loss of $0.09 per share; one report characterized this as a $0.02-per-share miss against its consensus estimate. The revenue shortfall and continuing losses may weigh on sentiment. CytomX Q3 Results
• Negative Sentiment: The clinical-program outlook carries execution risk, and the cited analysis notes prior dilution and terminated legacy partnerships as concerns that have pressured revenue. CytomX Stock Trading Near Cash Value

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.